{"entity":{"id":"in-111-pentetreotide","kind":"drug","name":"Indium-111 pentetreotide","aka":["111In-pentetreotide","OctreoScan"],"tldr":"The original nuclear medicine scan for finding neuroendocrine tumours, used before PET scans like Ga-68 DOTATATE became available. It is still FDA-approved but has largely been superseded because PET gives sharper pictures with less radiation.","summary":"OctreoScan (kit for the preparation of indium In-111 pentetreotide) was approved by FDA in 1994 (NDA 020314) and is still marketed, now by Curium, as a two-vial kit that the radiopharmacy combines before injection. It is indicated for scintigraphic localisation of primary and metastatic neuroendocrine tumours bearing somatostatin receptors, at a recommended dose of 111 MBq (3 mCi) for planar imaging or 222 MBq (6 mCi) for SPECT.\n\nOctreoScan was the standard-of-care functional imaging test for neuroendocrine tumours for roughly two decades, but head-to-head studies have consistently shown that the newer PET tracers (68Ga-DOTATATE, 68Ga-DOTATOC, 64Cu-DOTATATE) detect more lesions with better spatial resolution and lower radiation dose, and most guideline bodies (SNMMI, ENETS) now favour SSTR-PET where it is available. OctreoScan remains relevant where PET access is limited, and it has a long track record: the label carries specific precautions for insulinoma patients, who can develop severe hypoglycaemia with unlabelled octreotide co-administration, and the finished radiopharmaceutical must be used within six hours of preparation.","status":"approved","asOf":"2026-09-22","links":[{"label":"FDA label: Octreoscan (kit for the preparation of Indium In 111 Pentetreotide Injection)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020314Orig1s000Lbl.pdf"}],"tags":["SSTR2","SPECT","legacy agent"],"related":["cu-64-dotatate","ga-68-dotatoc","ga68-dotatate","ga-68","in-111","cu-64"],"indications":["neuroendocrine","pancreatic-net","small-intestinal-net"],"sections":[],"technologies":["spect","spect-ct"],"targets":["sstr2"],"drugs":[],"companies":["curium"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"OctreoScan","modality":"SPECT tracer","mechanism":"Pentetreotide is an octreotide derivative conjugated to the chelator DTPA; once labelled with indium-111 it binds somatostatin receptor subtype 2 on neuroendocrine tumour cells. Because indium-111 is a gamma emitter rather than a positron emitter, imaging is by SPECT (or SPECT/CT) rather than PET.","approvals":[{"region":"US","year":1994,"indication":"Scintigraphic localisation of primary and metastatic neuroendocrine tumours bearing somatostatin receptors"}],"mechanismSteps":[],"dosing":{"route":"Intravenous injection, after radiolabelling the kit","schedule":"111 MBq (3 mCi) for planar imaging; 222 MBq (6 mCi) for SPECT imaging; use within 6 hours of preparation","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020314Orig1s000Lbl.pdf"},"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/in-111-pentetreotide/","neighbours":{"drug":[{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/"},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/"},{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/"},{"id":"tc-99m-psma-imaging","kind":"drug","name":"Technetium Tc-99m PSMA agents (PSMA-I&S)","route":"/drugs/tc-99m-psma-imaging/"}],"isotope":[{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/"}],"indication":[{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/"}],"technology":[{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/"}]}}